ARTICLE | Clinical News
Ropeginterferon alfa-2b: Final Ph III PROUD-PV data
December 30, 2016 1:53 AM UTC
Final data from the open-label, European Phase III PROUD-PV trial in 254 patients with PV showed that 50-500 µg subcutaneous ropeginterferon alfa-2b every other week was non-inferior to once-daily ora...